Cost-Effectiveness Analysis of 68Ga DOTA-TATE PET/CT, 111In-Pentetreotide SPECT/CT and CT for Diagnostic Workup of Neuroendocrine Tumors

• Published in: Diagnostics (Basel) Vol. 11; no. 2; p. 334
• Main Authors: Froelich, Matthias Frank, Schnitzer, Moritz Ludwig, Holzgreve, Adrien, Gassert, Felix Gerhard, Gresser, Eva, Overhoff, Daniel, Schwarze, Vincent, Fabritius, Matthias Philipp, Nörenberg, Dominik, von Münchhausen, Niklas, Hokamp, Nils Große, Auernhammer, Christoph J., Ilhan, Harun, Todica, Andrei, Rübenthaler, Johannes
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 18.02.2021; MDPI
• Subjects: 68Ga-DOTA-TATE PET/CT; Cost analysis; cost-effectiveness; Diagnostic tests; Disease; Gamma rays; Magnetic resonance imaging; Medical imaging; Medical prognosis; Metastasis; Neuroendocrine tumors; nuclear imaging; Tomography; United States > US
• ISSN: 2075-4418; 2075-4418
• DOI: 10.3390/diagnostics11020334

Neuroendocrine tumors (NETs) are relatively rare neoplasms arising from the hormone-producing neuroendocrine system that can occur in various organs such as pancreas, small bowel, stomach and lung. As the majority of these tumors express somatostatin receptors (SSR) on their cell membrane, utilization of SSR analogs in nuclear medicine is a promising, but relatively costly approach for detection and localization. The aim of this study was to analyze the cost-effectiveness of 68Ga-DOTA-TATE PET/CT (Gallium-68 DOTA-TATE Positron emission tomography/computed tomography) compared to 111In-pentetreotide SPECT/CT (Indium-111 pentetreotide Single Photon emission computed tomography/computed tomography) and to CT (computed tomography) alone in detection of NETs. A decision model on the basis of Markov simulations evaluated lifetime costs and quality-adjusted life years (QALYs) related to either a CT, SPECT/CT or PET/CT. Model input parameters were obtained from publicized research projects. The analysis is grounded on the US healthcare system. Deterministic sensitivity analysis of diagnostic parameters and probabilistic sensitivity analysis predicated on a Monte Carlo simulation with 30,000 reiterations was executed. The willingness-to-pay (WTP) was determined to be $ 100,000/QALY. In the base-case investigation, PET/CT ended up with total costs of $88,003.07 with an efficacy of 4.179, whereas CT ended up with total costs of $88,894.71 with an efficacy of 4.165. SPECT/CT ended up with total costs of $89,973.34 with an efficacy of 4.158. Therefore, the strategies CT and SPECT/CT were dominated by PET/CT in the base-case scenario. In the sensitivity analyses, PET/CT remained a cost-effective strategy. This result was due to reduced therapy costs of timely detection. The additional costs of 68Ga-DOTA-TATE PET/CT when compared to CT alone are justified in the light of potential savings in therapy costs and better outcomes.